Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

161.59 +0.02 (+0.01%)
Streaming Delayed Price Updated: 10:50 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Growth Stock with Exciting Potential and 2 to Be Wary Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
Here's How Much $100 Invested In Natera 10 Years Ago Would Be Worth Today
Via Benzinga
1 Volatile Stock to Own for Decades and 2 to Brush Off
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Earnings Scheduled For May 8, 2025
Via Benzinga
Preview: Natera's Earnings
Via Benzinga
Peering Into Natera's Recent Short Interest
Via Benzinga
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 Reasons We Love Natera (NTRA)
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%. 
Via StockStory
Topics Government Stocks
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years
Via Benzinga
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue... 
Via StockStory
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
3 Mid-Cap Stocks Worth Your Attention
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses... 
Via StockStory
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Via Benzinga
8 Analysts Have This To Say About Natera
Via Benzinga
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98... 
Via StockStory
What To Expect From Natera’s (NTRA) Q1 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 to Turn Down
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Via Benzinga
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Assessing Natera: Insights From 10 Financial Analysts
Via Benzinga
3 Reasons NTRA Has Explosive Upside Potential
Natera currently trades at $141.03 and has been a dream stock for shareholders. It’s returned 351% since April 2020, blowing past the S&P 500’s 87.1% gain. The company has also beaten the index over... 
Via StockStory
Topics Government Stocks
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.